Clinical tumor specimens were subjected to immunohistochemical analysis, enabling the assessment of phospho-EGFR (p-EGFR) expression levels and the infiltration level of CD8+ tumor-infiltrating lymphocytes (TILs). The gene discussed is EGFR; the disease is neoplasm.